About Insightec
InSightec develops and manufactures MR-guided ultrasound technology devices for image-guided acoustic surgery.
Headquarters
Insightec, Tirat Carmel
Founded
1999-01-01
Industry
Biotechnology, Health Care, Manufacturing, Medical Device, Therapeutics
Last Funding Type
Private Equity
Valuation
3
Total Funding
$882.90 million dollars
IPO Status
Private
Financial
InSightec announced the availability of Exablate Prime, the next generation of MR-guided focused ultrasound, in Europe. Additionally, InSightec raised $150 million to enhance the therapeutic capabilities of its focused ultrasound technology.
INSIGHTEC Ltd. is focused on advancing MR-guided ultrasound technology for non-invasive surgeries. Their research includes systems for controlling drug delivery through tissue barriers, such as the blood-brain barrier, by using ultrasound to increase permeability. They are developing methods for image registration across different modalities, adhesive compositions for high-voltage ultrasound applications, and techniques for monitoring tissue permeability. Additionally, they are exploring conformal phased-array transducer arrangements, short-pulse sonodynamic treatment, and effective delivery of monoclonal antibodies. Their work also encompasses ultrasound autofocusing, variable-bandwidth transducers, and diagnostic technologies related to blood-brain barrier disruption. Each area aims to enhance precision and effectiveness in image-guided acoustic surgery.
InSightec, a healthcare company specializing in focused ultrasound technology, announced it has raised $150 million in equity financing. The funds will support the continued growth and development of its incision-less, ultrasound-based neurosurgery technology.
INSIGHTEC Ltd. is focused on advancing MR-guided ultrasound technology for non-invasive surgeries. Their research includes systems for controlling drug delivery through tissue barriers, such as the blood-brain barrier, by using ultrasound to increase permeability. They are developing methods for image registration across different modalities, adhesive compositions for high-voltage ultrasound applications, and techniques for monitoring tissue permeability. Additionally, they are exploring conformal phased-array transducer arrangements, short-pulse sonodynamic treatment, and effective delivery of monoclonal antibodies. Their work also encompasses ultrasound autofocusing, variable-bandwidth transducers, and diagnostic technologies related to blood-brain barrier disruption. Each area aims to enhance precision and effectiveness in image-guided acoustic surgery.
InSightec, a healthcare company specializing in focused ultrasound technology, announced it has raised $150 million in equity financing. The funds will support the continued growth and development of its incision-less, ultrasound-based neurosurgery technology.
Funding Rounds
12
Number of Lead Investors
7
Total Funding Amount
$882.90 million dollars
Number of Investors
20